FILAMENT HEALTH ANNOUNCES FIRST QUARTER 2025 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS
VANCOUVER, BC, /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (CBOE: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical-stage natural psychedelic drug development company, released its first quarter financial results and operational highlights for the period ended March 31, 2025.
"This quarter we were pleased to see positive data from a clinical trial studying our botanical psilocybin drug candidate, PEX010, for alcohol use disorder at Psychiatric Centre Copenhagen, among other notable operational developments," said Benjamin Lightburn, Co-Founder and Chief Executive Officer at Filament Health. "We were also encouraged by the successful completion of a meaningful fundraising round. This progress demonstrates our team's resilience and commitment to advancing our mission."
Recent and Q1 2025 Financial and Operational Highlights:
On April 9, 2025, the Company announced FDA authorization of a phase 2 clinical trial studying PEX010, the Company's botanical psilocybin drug candidate, for the treatment of opioid use disorder at the University of Pennsylvania.
On April 9, 2025, the Company closed a financing of $960,000 further to the issuance of units, comprised of a secured convertible debenture of the company and a warrant.
On March 17, 2025, the Company announced that a licensing partner studying the effects of its botanical psilocybin drug candidate, PEX010, for the treatment of alcohol use disorder ("AUD") produced positive data and results were published in the Journal of Psychopharmacology noting the safety and efficacy in reducing alcohol consumption in AUD patients.
On January 21, 2025, the Company announced the shipment of botanical psilocybin to The University of Wisconsin-Madison for investigation in two US Food and Drug Administration-approved clinical trials studying the effects of psilocybin on neuroplasticity.
Cash and cash equivalents of $130,441 as of March 31, 2025;
Cash used in operating activities of $221,755 and total revenues of $103,480.
Special Shareholder Meeting
At a special shareholder meeting held on May 6, 2025, 99.625 percent of votes were cast in favour of the voluntary de-listing of the company's common shares from Cboe Canada. This strong support reflects shareholder alignment with the company's strategic direction and ongoing efforts to reduce operating costs. The Company is in active discussions with CBOE Canada regarding the de-listing and will share more information, such as when the Company's shares will be de-listed, as it becomes available.
ABOUT FILAMENT HEALTH (OTCQB:FLHLF) (CBOE CA:FH) (FSE:7QS)
Filament Health is a clinical-stage natural psychedelic drug development company. We believe that safe, standardized, naturally-derived psychedelic medicines can improve the lives of many, and our mission is to see them in the hands of everyone who needs them as soon as possible. Filament's platform of proprietary intellectual property enables the discovery, development, and delivery of natural psychedelic medicines for clinical development. We are paving the way with the first-ever natural psychedelic drug candidates.
Learn more at www.filament.health and on Twitter, Instagram and LinkedIn.
FORWARD LOOKING INFORMATION
Certain statements and information contained herein may constitute "forward-looking statements" and "forward-looking information," respectively, under Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as, "expect", "anticipate", "continue", "estimate", "may", "will", "should", "believe", "intends", "forecast", "plans", "guidance" and similar expressions are intended to identify forward-looking statements or information. Forward-looking statements herein include, but are not limited to, statements regarding the benefits of psilocin as compared to psilocybin. The forward-looking statements are not historical facts, but reflect the current expectations of management of Filament regarding future results or events and are based on information currently available to them. Certain material factors and assumptions were applied in providing these forward-looking statements. Forward-looking statements regarding the Company are based on the Company's estimates and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of Filament to be materially different from those expressed or implied by such forward-looking statements or forward-looking information, including results of the clinical trial. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Filament will not update any forward-looking statements or forward-looking information that are incorporated by reference herein, except as required by applicable securities laws.
SOURCE Filament Health Corp.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
13 hours ago
- Cision Canada
WALL FINANCIAL CORPORATION ANNOUNCES VOTING RESULTS FROM ITS ANNUAL GENERAL MEETING OF SHAREHOLDERS HELD ON JUNE 12, 2025
VANCOUVER, BC, June 13, 2025 /CNW/ - WALL FINANCIAL CORPORATION (TSX: WFC) (the "Company") announces the voting results from its annual general meeting of shareholders held on June 12, 2025 in Vancouver, British Columbia (the "AGM"). A total of 27 shareholders were represented at the meeting, being 80.4% of the Company's issued and outstanding common shares. Shareholders voted in favour of all matters brought before the AGM including setting the numbers at seven, and the appointment of auditors for the ensuing year. Detailed results of the proxy votes for the election of directors are provided below: About Wall Financial Corporation Wall Financial Corporation is a B.C. based real estate company active in the development and management of residential and commercial rental units, development and construction of residential housing for resale, and the development and management of hotel properties. SOURCE Wall Financial Corporation For further information, contact Bruno Wall, CEO and CFO, Wall Financial Corporation, 1010 Burrard Street, Vancouver, British Columbia V6Z 2R9, 604.893.7131.
Cision Canada
15 hours ago
- Cision Canada
Nanalysis Announces Closing of Fully Subscribed Note Offering
CALGARY, AB, /CNW/ - Nanalysis Scientific Corp. (the " Company" or " Nanalysis") (TSXV: NSCI, OTCQX: NSCIF, FRA: 1N1), is pleased to announce that it has closed its previously-announced offering of 12% unsecured promissory notes (the " Notes") for aggregate gross proceeds of $2,000,000 (the " Offering"). The Notes were issued to arm's length third-party investors (the " Lenders"). The Notes mature on June 13, 2027, and bear simple interest at a rate of 12% per annum, payable annually within 30 days of the first and second anniversary date of the Notes. At the Company's option and subject to TSX Venture Exchange (" TSXV") approval, the interest may be paid in cash or common shares of the Company. The Company intends to use the net proceeds from the Offering for general corporate purposes and to support ongoing business operations. In connection with the Notes, the Company has issued 1,600,000 common shares of the Company (the " Bonus Shares") to the Lenders. The Bonus Shares represent a value equal to 20% of the principal amount of the Notes, calculated based on the Market Price (as defined by the TSXV) of $0.25 per Bonus Share, which was the closing price of the Company's common shares on June 5, 2025 prior to the announcement of the Offering. The Bonus Shares are subject to a four month hold period, expiring October 13, 2025, in accordance with applicable securities legislation. About Nanalysis Scientific Corp. (TSXV: NSCI, OTCQX: NSCIF, FRA: 1N1) Nanalysis Scientific Corp. in operates two primary business segments: Scientific Equipment and Security Services. Within its Scientific Equipment business is what the Company terms "MRI and NMR for industry". The Company develops and manufactures portable Nuclear Magnetic Resonance (NMR) spectrometers or analyzers for laboratory and industrial markets. The NMReady-60™ was the first full-feature portable NMR spectrometer in a single compact enclosure requiring no liquid helium or any other cryogens. The Company has followed up that initial offering with new products and continues to have a strong innovation pipeline. In 2020, the Company announced the launch of its 100MHz platform, which has the highest usable field on a fully featured benchtop NMR on the market. In early 2025, the Company launched its new 60MHz instrument which is based on the successful 100MHz product line. The Company's devices are used in many industries (oil and gas, chemical, mining, pharma, biotech, flavor and fragrances, agrochemicals, law enforcement, and more) as well as numerous government and university research labs around the world. The Company is working to expand into new global market opportunities independently and with partners. With its partners, the Company provides scientific equipment sales and maintenance services globally. Within the Company's Security Services business, the core activity is providing airport security equipment maintenance in each province and territory of Canada. In addition, the Company provides commercial security equipment installation and maintenance services to a variety of customers in North America. Notice regarding Forward Looking Information and Legal Disclaimer This news release contains certain forward-looking information. All statements included herein, other than statements of historical fact, are forward-looking information and such information involves various risks and uncertainties. In particular, this news release contains forward-looking information in relation to: the use of proceeds of the Offering; payment of interest on the Notes in cash or common shares, subject to TSXV approval. There can be no assurance that such information will prove to be accurate, and actual results and future events could differ materially from those anticipated in such information. This forward-looking information reflects Nanalysis's current beliefs and is based on information currently available to Nanalysis and on assumptions Nanalysis believes are reasonable. These assumptions include, but are not limited to: the current share price of Nanalysis's common shares; TSXV acceptance and market acceptance of the offering; Nanalysis' general and administrative costs remaining constant; and market acceptance of Nanalysis's business model, goals and approach. Forward-looking information is subject to known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Nanalysis to be materially different from those expressed or implied by such forward-looking information. Statements with forward looking information are based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. Readers should not place undue reliance on forward-looking information. Nanalysis does not undertake to update any forward-looking information except in accordance with applicable securities laws. This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") or any state securities laws and may not be offered or sold within the United States or to, or for the account or benefit of, U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws, unless an exemption from such registration is available.
Cision Canada
16 hours ago
- Cision Canada
Cascades Announces that its Subsidiary Greenpac Mill, LLC Has Successfully Refinanced its Bank Debt
KINGSEY FALLS, QC, June 13, 2025 /CNW/ - Cascades Inc. (TSX: CAS) (the "Company"), announces that Greenpac Mill, LLC ("Greenpac"), the Company's 86.35% owned subsidiary, has successfully entered into an agreement to increase its existing revolving credit facility to US$250 million from US$150 million previously. Concurrently, the facility's maturity has been extended from December 2027 to June 2028. All other terms remain unchanged. National Bank Financial Markets acted as Lead Arranger and Sole Bookrunner on this transaction. The financing is provided by a syndicate of lenders comprised of National Bank of Canada, M&T Bank, Bank of America, N.A. and Comerica Bank. The Greenpac Mill, located in Niagara Falls, New York, manufactures lightweight containerboard, made with 100% recycled fibres. Founded in 1964, Cascades offers sustainable, innovative and value-added packaging, hygiene and recovery solutions. The company employs approximately 9,600 women and men across a network of 66 operating facilities, including 17 Recovery and Recycling facilities which are part of Corporate Activities and joint ventures managed by the Corporation, in North America. Driven by its participative management, half a century of experience in recycling, and continuous research and development efforts, Cascades continues to provide innovative products that customers have come to rely on, while contributing to the well-being of people, communities and the entire planet. Cascades' shares trade on the Toronto Stock Exchange under the ticker symbol CAS.
